Titan Historical Financial Ratios
| TTNP Stock | USD 3.68 0.19 4.91% |
Titan Pharmaceuticals is promptly reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 2.58, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 7.94 will help investors to properly organize and evaluate Titan Pharmaceuticals financial condition quickly.
Titan |
About Titan Financial Ratios Analysis
Titan PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Titan Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Titan financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Titan Pharmaceuticals history.
Titan Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Titan Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Titan Pharmaceuticals sales, a figure that is much harder to manipulate than other Titan Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Titan Pharmaceuticals dividend as a percentage of Titan Pharmaceuticals stock price. Titan Pharmaceuticals dividend yield is a measure of Titan Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Titan Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Titan Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.At this time, Titan Pharmaceuticals' Days Sales Outstanding is relatively stable compared to the past year. As of 03/28/2025, Stock Based Compensation To Revenue is likely to grow to 7.94, while Book Value Per Share is likely to drop 2.58.
| 2024 | 2025 (projected) | Dividend Yield | 0.001708 | 0.001518 | Price To Sales Ratio | 38.78 | 36.84 |
Titan Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Titan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Titan Pharmaceuticals fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 2.57 | 6.5 | 174.64 | 33.72 | 38.78 | 36.84 | |
| Ptb Ratio | 3.51 | 1.93 | 7.69 | 0.93 | 1.2 | 1.14 | |
| Days Sales Outstanding | 66.69 | 26.79 | 219.0 | 2.1K | 1.9K | 2.0K | |
| Book Value Per Share | 18.72 | 10.56 | 2.03 | 8.83 | 2.71 | 2.58 | |
| Free Cash Flow Yield | (1.43) | (0.8) | (0.78) | (1.14) | (1.32) | (1.39) | |
| Operating Cash Flow Per Share | (91.19) | (16.24) | (12.18) | (9.43) | (4.32) | (4.53) | |
| Stock Based Compensation To Revenue | 0.001447 | 0.99 | 16.62 | 5.51 | 6.33 | 7.94 | |
| Capex To Depreciation | 1.05 | 1.85 | 0.1 | 0.0179 | 0.0161 | 0.0153 | |
| Pb Ratio | 3.51 | 1.93 | 7.69 | 0.93 | 1.2 | 1.14 | |
| Ev To Sales | 1.61 | 2.74 | 128.81 | 0.0489 | 0.0563 | 0.0534 | |
| Free Cash Flow Per Share | (94.05) | (16.28) | (12.18) | (9.43) | (4.32) | (4.53) | |
| Roic | (4.58) | (1.56) | (6.1) | (1.01) | (1.87) | (1.96) | |
| Inventory Turnover | 1.29 | 1.44 | 0.68 | 1.85 | 1.66 | 0.91 | |
| Net Income Per Share | (109.88) | (16.68) | (15.15) | (7.41) | (5.23) | (5.5) | |
| Days Of Inventory On Hand | 282.82 | 253.64 | 537.41 | 197.4 | 177.66 | 189.1 | |
| Payables Turnover | 1.58 | 0.38 | 0.25 | 0.28 | 0.32 | 0.29 | |
| Sales General And Administrative To Revenue | 1.2 | 3.27 | 100.57 | 30.15 | 34.67 | 52.45 | |
| Research And Ddevelopement To Revenue | 1.22 | 3.73 | 79.3 | 10.4 | 11.96 | 11.36 | |
| Capex To Revenue | 0.0709 | 0.11 | 0.0151 | 0.0109 | 0.0125 | 0.0119 | |
| Cash Per Share | 28.69 | 12.41 | 4.37 | 8.99 | 3.15 | 2.99 | |
| Pocfratio | (0.72) | (1.26) | (1.28) | (0.87) | (0.76) | (0.79) | |
| Capex To Operating Cash Flow | (0.0166) | (0.0314) | (0.002912) | (2.82E-4) | (2.54E-4) | (2.41E-4) | |
| Pfcf Ratio | (0.7) | (1.25) | (1.28) | (0.87) | (0.76) | (0.79) | |
| Days Payables Outstanding | 968.95 | 1.5K | 1.3K | 1.1K | 1.0K | 1.1K | |
| Roe | (5.87) | (1.58) | (7.47) | (0.84) | (1.93) | (2.03) | |
| Ev To Operating Cash Flow | (0.45) | (0.53) | (0.94) | (0.001269) | (0.0257) | (0.027) | |
| Pe Ratio | (0.6) | (1.22) | (1.03) | (1.11) | (0.62) | (0.65) | |
| Return On Tangible Assets | (0.64) | (1.69) | (2.56) | (1.02) | (2.51) | (0.69) | |
| Ev To Free Cash Flow | (0.44) | (0.53) | (0.94) | (0.001269) | (0.0257) | (0.027) | |
| Earnings Yield | (1.67) | (0.82) | (0.97) | (0.9) | (1.61) | (1.69) | |
| Current Ratio | 1.74 | 2.71 | 1.37 | 5.55 | 6.05 | 8.27 | |
| Tangible Book Value Per Share | 18.72 | 10.56 | 2.03 | 8.83 | 2.71 | 2.58 | |
| Receivables Turnover | 5.47 | 13.63 | 1.67 | 0.18 | 0.2 | 0.19 | |
| Shareholders Equity Per Share | 18.72 | 10.56 | 2.03 | 8.83 | 2.71 | 2.58 | |
| Debt To Equity | 0.23 | 0.0582 | 0.14 | 0.0851 | 0.0766 | 0.0727 | |
| Capex Per Share | 200.52 | 2.86 | 0.0473 | 0.00266 | 0.002394 | 0.002274 | |
| Graham Net Net | 8.93 | 7.01 | 0.48 | 8.11 | 2.61 | 2.48 |
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.